
Human Rabies Vaccines Market by Cell Line Type (BHK Cells, Chick Embryo Cells, Vero Cell), Route of Administration (Intravenous, Subcutaneous), Application, Distribution Channel - Global Forecast 2024-2030
Description
Human Rabies Vaccines Market by Cell Line Type (BHK Cells, Chick Embryo Cells, Vero Cell), Route of Administration (Intravenous, Subcutaneous), Application, Distribution Channel - Global Forecast 2024-2030
The Human Rabies Vaccines Market size was estimated at USD 1.01 billion in 2023 and expected to reach USD 1.05 billion in 2024, at a CAGR 4.51% to reach USD 1.37 billion by 2030.
Global Human Rabies Vaccines Market
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Human Rabies Vaccines Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Human Rabies Vaccines Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Human Rabies Vaccines Market, highlighting leading vendors and their innovative profiles. These include Bavarian Nordic A/S, Bharat Biotech International Limited, Cadila Pharmaceuticals Ltd., CSC Pharmaceutical International, Indian Immunologicals Limited, Merck & Co Inc., Novartis International AG, Pfizer Inc., Sanofi SA, Serum Institute of India, Virbac, and Wyeth, LLC.
Market Segmentation & Coverage
This research report categorizes the Human Rabies Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:
Cell Line Type
BHK Cells
Chick Embryo Cells
Vero Cell
Route of Administration
Intravenous
Subcutaneous
Application
Post Exposure Prophylaxis
Pre Exposure Prophylaxis
Distribution Channel
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Human Rabies Vaccines Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Human Rabies Vaccines Market?
3. What are the technology trends and regulatory frameworks in the Human Rabies Vaccines Market?
4. What is the market share of the leading vendors in the Human Rabies Vaccines Market?
5. Which modes and strategic moves are suitable for entering the Human Rabies Vaccines Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
193 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Human Rabies Vaccines Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising prevalence of mortality due to rabies
- 5.1.1.2. Increasing number of pets and stray dogs
- 5.1.1.3. Lower rate of immunization in pets and lack of pet management services
- 5.1.2. Restraints
- 5.1.2.1. Dearth of vaccine supply in remote areas
- 5.1.3. Opportunities
- 5.1.3.1. Proliferation in research and development activities to introduce effective vaccine
- 5.1.3.2. Rising entry of new market players in the production of vaccine
- 5.1.4. Challenges
- 5.1.4.1. Reduced awareness in emerging economies
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Human Rabies Vaccines Market, by Cell Line Type
- 6.1. Introduction
- 6.2. BHK Cells
- 6.3. Chick Embryo Cells
- 6.4. Vero Cell
- 7. Human Rabies Vaccines Market, by Route of Administration
- 7.1. Introduction
- 7.2. Intravenous
- 7.3. Subcutaneous
- 8. Human Rabies Vaccines Market, by Application
- 8.1. Introduction
- 8.2. Post Exposure Prophylaxis
- 8.3. Pre Exposure Prophylaxis
- 9. Human Rabies Vaccines Market, by Distribution Channel
- 9.1. Introduction
- 9.2. Hospital Pharmacy
- 9.3. Online Pharmacy
- 9.4. Retail Pharmacy
- 10. Americas Human Rabies Vaccines Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Human Rabies Vaccines Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.
- 10. South Korea
- 11.
- 11. Taiwan
- 11.
- 12. Thailand
- 11.
- 13. Vietnam
- 12. Europe, Middle East & Africa Human Rabies Vaccines Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.
- 10. Nigeria
- 12.
- 11. Norway
- 12.
- 12. Poland
- 12.
- 13. Qatar
- 12.
- 14. Russia
- 12.
- 15. Saudi Arabia
- 12.
- 16. South Africa
- 12.
- 17. Spain
- 12.
- 18. Sweden
- 12.
- 19. Switzerland
- 12.
- 20. Turkey
- 12.
- 21. United Arab Emirates
- 12.
- 22. United Kingdom
- 13. Competitive Landscape
- 13.1. FPNV Positioning Matrix
- 13.2. Market Share Analysis, By Key Player
- 13.3. Competitive Scenario Analysis, By Key Player
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.1.1. Bavarian Nordic A/S
- 14.1.2. Bharat Biotech International Limited
- 14.1.3. Cadila Pharmaceuticals Ltd.
- 14.1.4. CSC Pharmaceutical International
- 14.1.5. Indian Immunologicals Limited
- 14.1.6. Merck & Co Inc.
- 14.1.7. Novartis International AG
- 14.1.8. Pfizer Inc.
- 14.1.9. Sanofi SA
- 14.1.
- 10. Serum Institute of India
- 14.1.
- 11. Virbac
- 14.1.
- 12. Wyeth, LLC
- 14.2. Key Product Portfolio
- 15. Appendix
- 15.1. Discussion Guide
- 15.2. License & Pricing
- FIGURE 1. HUMAN RABIES VACCINES MARKET RESEARCH PROCESS
- FIGURE 2. HUMAN RABIES VACCINES MARKET SIZE, 2023 VS 2030
- FIGURE 3. HUMAN RABIES VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. HUMAN RABIES VACCINES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. HUMAN RABIES VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. HUMAN RABIES VACCINES MARKET DYNAMICS
- FIGURE 7. HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2023 VS 2030 (%)
- FIGURE 8. HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
- FIGURE 10. HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
- FIGURE 12. HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
- FIGURE 14. HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 18. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 23. HUMAN RABIES VACCINES MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 24. HUMAN RABIES VACCINES MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.